Nanalysis Scientific Corp. reports developments tied to portable Nuclear Magnetic Resonance spectrometers, MRI and imaging technology, and related services for industrial and research applications. Company updates describe instruments used in pharmaceutical, biotech, energy, food, materials, security, academic, and government settings, as well as a services division that maintains Nanalysis products and third-party imaging equipment.
Recurring news themes include quarterly and annual results, conference-call announcements, supply-chain and market-diversification updates, non-dilutive funding, private placement financings, equity incentive grants, and board composition changes. The company also references its long-term Canadian Air Transport Security Authority relationship for security-scanner maintenance at Canadian airports.
Nanalysis (NSCIF) appointed Philip Birkby as Interim Chief Financial Officer, effective October 5, 2026, succeeding Heather Kury, whose tenure has concluded.
Birkby is a chartered professional accountant with more than 25 years of experience in public and private organizations, primarily in energy and financial services. His background includes financial reporting, corporate finance, treasury, risk management and corporate governance, along with work with executive teams and boards on liquidity, financing and capital structure.
Nanalysis Scientific (OTC: NSCIF) reported Q2 2026 revenue of $9.7 million, up 1.5% year over year, driven by higher Security Services and flow-through revenue, partially offset by lower product sales after terminating third‑party equipment sales.
Product sales fell 3.6% to $2.8 million, while services revenue grew 3.9% to $5.8 million and flow‑through revenue increased 2.9% to $1.1 million. Product gross margin rose to 65% and Security Services gross margin to 12%, both improving versus Q2 2025. Adjusted EBITDA turned positive to $0.9 million from a $0.5 million loss, and net loss narrowed to $0.7 million. For the first half of 2026, revenue was $20.4 million with Adjusted EBITDA of $1.2 million, and net loss reduced to $1.9 million. The company remained in compliance with all ATB debt covenants and secured $1.0 million PrairiesCan RTRI funding plus loan deferrals to support technology development and operations.
Nanalysis Scientific (OTC: NSCIF) will release its second quarter 2026 results before market open on Monday, August 24, 2026, followed by a conference call at 10:00 a.m. Eastern Time hosted by CEO Sean Krakiwsky and CFO Heather Kury via Zoom.
Investors can access the call using the published Zoom link, Meeting ID 831 7132 1596 and Passcode 331001. The webcast will be archived on Nanalysis’ investor relations webpage for at least 90 days. According to the company, Nanalysis develops portable NMR spectrometers and operates a services division anchored by a $160 million long-term CATSA contract.
Nanalysis (OTC:NSCIF, TSXV:NSCI) announced equity compensation grants to a director and officer. The board approved 100,000 stock options exercisable at $0.15 per share for five years and 100,000 restricted share units to an officer, under shareholder-approved equity plans.
Nanalysis Scientific (OTCQX:NSCIF) announced multiple updates, including quantum and MRI technology partnerships, government funding, capital raises and leadership changes.
Key items include a collaboration with NVision Quantum Technologies, expanded work with IMRIS, a $1 million non‑repayable PrairiesCan contribution, a $132,500 insider-led private placement, stock option grants, and the permanent appointment of Heather Kury as CFO.
Nanalysis (OTC:NSCIF) reported Q1 2026 revenue of $10.7 million, up 1% year over year, and Adjusted EBITDA of $292 thousand, up from $180 thousand. Net loss narrowed slightly to $1.28 million.
Product sales fell 41%, while security services revenue rose 18% and service margins improved to 19%. The company repaid about $3.4 million of ATB debt and continued cost-optimization and European sales expansion initiatives.
Nanalysis Scientific (OTC:NSCIF) will release its first quarter 2026 results after market close on Wednesday, May 20, 2026. Management will host a conference call at 10:00 a.m. ET on Thursday, May 21, 2026 to discuss the results.
The live event will be accessible via Zoom, and an archived webcast will be available on the company’s investor relations webpage for at least 90 days, allowing investors to review the discussion on demand.
Nanalysis (OTC: NSCIF) announced board changes effective May 1, 2026: Jonathan Ladd, Werner Maas, and Steve Feick were appointed to the board, while Martin Burian and Jennifer Stubbs stepped down. The appointments add experience in portable NMR/MRI instrumentation, global commercialization, and capital allocation to support scaling and services growth.
Nanalysis (OTC: NSCIF) reported Q4 2025 revenue of $10.7 million (down 13% YoY) and full-year revenue of $40.1 million (down 12% YoY). Q4 adjusted EBITDA returned to positive at $1.2 million; full-year adjusted EBITDA was $0.9 million. Product sales fell, services grew 5% for the year, and product gross margin improved to 57% for 2025.
Management cited supply‑chain diversification, cost reductions, a $3.4M private placement, $1.0M non‑dilutive funding, and signed distribution and associate contracts as strategic actions to stabilize operations and improve 2026 performance.
Nanalysis (TSXV: NSCI / OTC: NSCIF) will release fourth quarter and full year 2025 results after market close on Wednesday, April 8, 2026. CEO Sean Krakiwsky and Interim CFO Heather Kury will host a conference call at 10:00 AM ET on Thursday, April 9, 2026.
Investors can join via Zoom (meeting ID and passcode provided) and a webcast archive will be available on the company investor relations webpage for at least 90 days.